US OPTUM database study in polycythemia vera patients: Thromboembolic events (TEs) with hydroxyurea (HU) vs ruxolitinib switch therapy and machine-learning model to predict incidence of TEs and HU failure

Analysis of polycythemia vera patient data, from the OPTUM database of claims data and electronic medical records, demonstrated that those patients who switched to ruxolitinib therapy after initial treatment with hydroxyurea experienced a decrease in incidence (17% to 15%) of thromboembolic events, compared with an increase among those patients who continued receiving hydroxyurea therapy (13% to 20%).